[New approval: Atezolizumab and bevacizumab for first line of unresecable hepatocellular carcinoma].
作者信息
Minot-This Marie-Sophie, Edeline Julien
机构信息
Institut Gustave-Roussy, Sorbonne Université, service d'oncologie digestive, 94800 Villejuif, France.
Centre hospitalier universitaire de Rennes, centre Eugène-Marquis, service d'oncologie digestive, 35000 Rennes, France.
出版信息
Bull Cancer. 2021 Feb;108(2):139-140. doi: 10.1016/j.bulcan.2020.11.011. Epub 2021 Feb 2.
PMID:33546873
Abstract
摘要
相似文献
1
[New approval: Atezolizumab and bevacizumab for first line of unresecable hepatocellular carcinoma].
Bull Cancer. 2021 Feb;108(2):139-140. doi: 10.1016/j.bulcan.2020.11.011. Epub 2021 Feb 2.
2
Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.
Lancet Oncol. 2021 Jul;22(7):991-1001. doi: 10.1016/S1470-2045(21)00151-0. Epub 2021 May 27.
3
Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma.
JAMA Netw Open. 2021 Feb 1;4(2):e210037. doi: 10.1001/jamanetworkopen.2021.0037.
4
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.
Lancet Oncol. 2020 Jun;21(6):808-820. doi: 10.1016/S1470-2045(20)30156-X.
5
Favorable response to second-line atezolizumab and bevacizumab following progression on nivolumab in advanced hepatocellular carcinoma: A case report demonstrating that anti-VEGF therapy overcomes resistance to checkpoint inhibition.
Medicine (Baltimore). 2021 Jun 25;100(25):e26471. doi: 10.1097/MD.0000000000026471.
6
Case Report: Complete Response of Primary Massive Hepatocellular Carcinoma to Anti-Programmed Death Ligand-1 Antibody Following Progression on Anti-Programmed Death-1 Antibody.
Front Immunol. 2021 Aug 24;12:712351. doi: 10.3389/fimmu.2021.712351. eCollection 2021.
7
Portal hypertension is associated with poorer outcome and clinical liver decompensation in patients with HCC treated with Atezolizumab-Bevacizumab.
Dig Liver Dis. 2024 Sep;56(9):1621-1630. doi: 10.1016/j.dld.2024.02.018. Epub 2024 Mar 27.
8
FDA Approval Summary: Atezolizumab Plus Bevacizumab for the Treatment of Patients with Advanced Unresectable or Metastatic Hepatocellular Carcinoma.
Clin Cancer Res. 2021 Apr 1;27(7):1836-1841. doi: 10.1158/1078-0432.CCR-20-3407. Epub 2020 Nov 2.
9
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
N Engl J Med. 2020 May 14;382(20):1894-1905. doi: 10.1056/NEJMoa1915745.
10
Atezolizumab plus bevacizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a cost-effectiveness analysis.
Cancer Commun (Lond). 2020 Dec;40(12):743-745. doi: 10.1002/cac2.12110. Epub 2020 Nov 7.
Zotero 插件